Alzheimer's Archives

News and Trends 21 Dec 2017

Scientists Find New Immune Target to Stop Progression of Alzheimer’s

Scientists have described a new mechanism by which the immune system can drive Alzheimer’s and shown that blocking it can prevent the disease in mice. A study published yesterday in Nature details how a molecule involved in the innate immune response can promote the aggregation of amyloid-β plaques that appear in the brains of patients […]

December 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Nov 2017

Finnish Scientists Find Brain Cells Involved in Alzheimer’s Disease

Alzheimer’s disease is rapidly increasing in prevalence but we have no effective treatment. But, Finnish Researchers have found a new target to investigate. Researchers at the University of East Finland have found that astrocytes, the cells that support the brain, could play a major role in the pathogenesis of Alzheimer’s disease. The research, published in […]

November 22, 2017 - 3 minutesmins - By Alex Dale

hummingbird diagnostics cancer alzheimer parkinson

News and Trends 16 Nov 2017

German Diagnostics Firm Tackles Early Detection of Cancer, Alzheimer’s and Parkinson’s

Hummingbird Diagnostics has teamed up with Saarland University to develop molecular diagnostics that can detect serious diseases early using blood samples. Based in Heidelberg, Germany, Hummingbird Diagnostics develops early diagnostics in multiple disease areas, ranging from cancer to cardiovascular and neurodegenerative disease. Its technology is based in the detection of miRNA, molecules that are involved […]

November 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Nov 2017

Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II

AC Immune’s Anti-Tau antibody for the treatment of Alzheimer’s disease has reached Phase II, prompting milestone payments from Genentech. Today, the first patient in a Phase II trial was dosed with AC Immune’s anti-Tau antibody for the treatment of Alzheimer’s disease. This triggered a milestone payment of CHF 14M (€12M) from its collaborator, Genentech, as part of an agreement […]

November 2, 2017 - 2 minutesmins - By Alex Dale

News and Trends 16 Oct 2017

German Drug to Stop the Progression of Alzheimer’s Enters Phase IIb

Probiodrug is ready to start a Phase IIb trial with an Alzheimer’s drug that prevents the formation of Aβ plaques before the disease progresses. The German biotech Probiodrug is getting ready to start two Phase II trials to study the safety and efficacy of its candidate PQ912, a drug designed to intervene in the early stages of […]

October 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

artificial intelligence alzheimers neuroscience

In Depth 21 Sep 2017

How Will Artificial Intelligence Impact Alzheimer’s Research?

Last week, worldwide leaders gathered at the Artificial Intelligence in Bioscience Symposium in London to examine the growing role AI plays in healthcare, highlighting neuroscience and particularly Alzheimer’s as one of the most promising applications of this new technology. Within the last few years, the field of bioscience witnessed an exponential expansion, especially with the development […]

September 21, 2017 - 5 minutesmins - By External Contributor

More News! 19 Sep 2017

Scottish Scientists Claim that the Genome Controls the Aging of the Brain

Scientists in Scotland claim gene expression in the brain is so precisely controlled that they could predict your age just by looking at your genome. Researchers at the University of Edinburgh believe that genes in the brain are expressed at very specific times during a person’s life to carry out particular functions. Changes were seen […]

September 19, 2017 - 2 minutesmins - By Alex Dale

Allergan Heptares Therapeutics alzheimers

News and Trends 1 Sep 2017

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

Allergan’s partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer’s disease. A year ago, Allergan signed a massive deal of up to €3Bn with Heptares Therapeutics for the development of drugs that target G-protein-coupled receptors (GPCRs), a protein superfamily that currently comprises the target of around […]

September 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

probiodrug alzheimers disease mechanism of action

News and Trends 30 Aug 2017

German Scientists Publish New Mechanism of Action Against Alzheimer’s

Researchers at the German biotech Probiodrug have published today the detailed mechanism of action of a drug that might succeed in treating Alzheimer’s where many others have failed. Probiodrug is developing a therapeutic antibody with a unique mode of action against Alzheimer’s, PBD-C06. The company announced yesterday the publication in the Journal of Biological Chemistry of the detailed binding […]

August 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Jul 2017

FREE White Paper! All You need to Know about Omics and Body Fat

What do you think when you hear the word ‘lipid’? I bet your thoughts include fat, energy, hormones, maybe cells? But what if I told you that lipids can also be considered as biomarkers? Very important biomarkers too that can be analyzed and identified using multiparametric statistical analysis! With more and more research focusing on […]

July 19, 2017 - 3 minutesmins - By External Contributor

News and Trends 5 Jul 2017

Cutting Through the BS in Biopharma: How To Spot Hype

Faced with the oft-quoted figure that 90% of clinical trials end in failure, how can patients, investors, and readers be spared more disappointment? After discussing failures in biotech at Refresh earlier in June, I headed to Copenhagen last week for the European Conference for Science Journalists to cajole a panel into discussing how some of these stories feature […]

July 5, 2017 - 4 minutesmins - By Evelyn Warner

Araclon Biotech Alzheimers Vaccine Spain Zaragoza

News and Trends 27 Jun 2017

A Spanish Vaccine to fight Alzheimer’s Before Symptoms Appear enters Phase II

Araclon Biotech will advance to Phase II with an Alzheimer’s vaccine that could succeed where many others have failed before. Araclon Biotech, in Zaragoza, Spain, has announced today the approval from the Spanish Agency of Medicines and Medical Devices to start a Phase II trial testing its Alzheimer’s vaccine in 120 patients in 22 centers across Europe. The […]

June 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us